Every record from Janoshik · page 7
The single largest contributor to the index and the de facto reference against which the other five labs are calibrated here. Measured offset against the reference laboratory is 0.000 pp. Full laboratory profile →
| Report | Compound | Supplier | Lot | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042758 | TB-500 | GGPeps | GGPE-2601-B9932 | 2026-Q2 | 99.52 | 4.92 | 94.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042596 | Tirzepatide | GGPeps | GGPE-2604-H8313 | 2026-Q2 | 99.30 | 1.04 | 99.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042086 | PT-141 (Bremelanotide) | TFC | TFC-2512-V7681 | 2026-Q2 | 99.17 | 3.34 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041804 | Tirzepatide | FGP | FGP-2605-R1831 | 2026-Q2 | 97.67 | 6.47 | 92.2 | Buyer-sourced | 2 | MARGINAL |
| AX-2026-042957 | Retatrutide | KP | KP-2604-N4308 | 2026-Q2 | 98.15 | 4.87 | 96.8 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042282 | Semaglutide | Homopeptide | HOMO-2604-M2254 | 2026-Q2 | 99.05 | 2.86 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041887 | Melanotan II | JEEP | JEEP-2604-R3923 | 2026-Q2 | 99.56 | 5.05 | 95.2 | Supplier-supplied | 0 | PASS |
| AX-2026-041515 | Retatrutide | QYB | QYB-2602-R6263 | 2026-Q2 | 98.73 | 5.16 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041463 | SS-31 (Elamipretide) | QYB | QYB-2512-H5402 | 2026-Q2 | 99.65 | 5.18 | 91.5 | Supplier-supplied | 0 | PASS |
| AX-2026-041523 | Retatrutide | QYB | QYB-2602-R6263 | 2026-Q2 | 99.10 | 5.51 | 90.7 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041311 | Ipamorelin | WWB | WWB-2604-E3153 | 2026-Q2 | 99.93 | 5.52 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041218 | Thymulin | WWB | WWB-2602-S2129 | 2026-Q2 | 99.63 | 4.40 | 105.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043457 | BPC-157 | WXT | WXT-2602-W4680 | 2026-Q2 | 98.16 | 4.80 | 88.9 | Supplier-supplied | 3 | MARGINAL |
| AX-2026-043136 | BPC-157 | SSA | SSA-2601-N6752 | 2026-Q2 | 97.75 | 4.32 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-042817 | TB-500 | GGPeps | GGPE-2605-J2051 | 2026-Q2 | 99.91 | 4.27 | 89.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042209 | Epitalon | Homopeptide | HOMO-2512-A1223 | 2026-Q2 | 99.93 | 7.83 | 100.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-042106 | Retatrutide | TFC | TFC-2512-G7985 | 2026-Q2 | 99.15 | 2.00 | 90.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041843 | Tirzepatide | JEEP | JEEP-2602-J2798 | 2026-Q2 | 99.53 | 4.56 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041618 | BPC-157 | QSC | QSC-2511-N8732 | 2026-Q2 | 99.93 | 5.13 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041431 | BPC-157 | QYB | QYB-2601-D4733 | 2026-Q2 | 99.93 | 3.32 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043524 | MK-677 (Ibutamoren mesylate) | BCH | BCH-2511-G7276 | 2026-Q2 | 98.36 | 4.68 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043255 | BPC-157 | SGN | SGN-2512-H1950 | 2026-Q2 | 99.06 | 4.99 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042323 | Tirzepatide | HJ | HJ-2605-D3120 | 2026-Q2 | 97.88 | 4.14 | — | Laboratory-retained | 2 | MARGINAL |
| AX-2026-041852 | ARA-290 | JEEP | JEEP-2601-K3139 | 2026-Q2 | 99.03 | 4.60 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041829 | BPC-157 | FGP | FGP-2601-E2289 | 2026-Q2 | 99.93 | 3.61 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041764 | MK-677 (Ibutamoren mesylate) | FGP | FGP-2604-K1470 | 2026-Q2 | 99.93 | 5.34 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042776 | BPC-157 | GGPeps | GGPE-2602-N9882 | 2026-Q2 | 98.68 | 5.73 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042137 | Hexarelin | Homopeptide | HOMO-2602-R8195 | 2026-Q2 | 99.93 | 3.94 | 90.6 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043527 | MK-677 (Ibutamoren mesylate) | BCH | BCH-2511-G7276 | 2026-Q2 | 98.35 | 4.36 | 95.5 | Supplier-supplied | 1 | FAIL |
| AX-2026-043341 | TB-500 | CPC | CPC-2605-B2433 | 2026-Q2 | 98.38 | 5.70 | — | Laboratory-retained | 2 | FAIL |
| AX-2026-042964 | Retatrutide | KP | KP-2604-N4308 | 2026-Q2 | 98.24 | 4.87 | — | Buyer-sourced | 2 | MARGINAL |
| AX-2026-042585 | SLU-PP-332 | GGPeps | GGPE-2511-R8569 | 2026-Q2 | 98.63 | 4.32 | 88.8 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042085 | PT-141 (Bremelanotide) | TFC | TFC-2512-V7681 | 2026-Q2 | 99.37 | 3.55 | 94.5 | Supplier-supplied | 0 | PASS |
| AX-2026-042020 | Liraglutide | TFC | TFC-2511-E6528 | 2026-Q2 | 98.68 | 3.85 | 89.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043385 | TB-500 | CPC | CPC-2603-C3192 | 2026-Q2 | 98.23 | 4.66 | 95.0 | Supplier-supplied | 1 | FAIL |
| AX-2026-043138 | BPC-157 | SSA | SSA-2601-N6752 | 2026-Q2 | 98.00 | 4.30 | 101.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043137 | BPC-157 | SSA | SSA-2601-N6752 | 2026-Q2 | 97.41 | 4.36 | 104.5 | Laboratory-retained | 1 | FAIL |
| AX-2026-043000 | TB-500 | KP | KP-2605-C4659 | 2026-Q2 | 99.63 | 5.34 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041817 | PT-141 (Bremelanotide) | FGP | FGP-2602-Y1702 | 2026-Q2 | 99.79 | 4.12 | 99.8 | Supplier-supplied | 0 | PASS |
| AX-2026-041430 | BPC-157 | QYB | QYB-2601-D4733 | 2026-Q2 | 99.53 | 3.27 | 102.9 | Laboratory-retained | 1 | MARGINAL |